0
Editorials: Point and Counterpoint |

POINT: Will New Anti-eosinophilic Drugs Be Useful in Asthma Management? Yes

Paul M. O'Byrne, MBBCh, FCCP
Author and Funding Information

FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: P. M. O. has held grants-in aid from GSK for the investigation of mepolizumab and from Medimmune for the investigation of benralizumab. He also reports consulting fees from AstraZeneca, Chiesi, Boehringer Ingelheim, GSK, Medimmune, Merck, Takeda, and Abbott and grants-in-aid from AstraZeneca, Amgen, Genentech, Novartis Axican, and Alakos.

Firestone Institute of Respiratory Health and the Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada

CORRESPONDENCE TO: Paul M. O’Byrne, MBBCh, FCCP, Room 3W10, McMaster University Medical Center, 1280 Main St W, Hamilton, ON, L8S 4K1, Canada


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2017;151(1):14-17. doi:10.1016/j.chest.2016.09.021
Text Size: A A A
Published online

Extract

Over the past 10 years, the aims of asthma management have focused on achieving overall asthma control, which consists of two domains: current (day-to-day) control of symptoms, minimizing the use of asthma relievers, maintaining activities of daily living, and reducing future risk of severe asthma exacerbations and asthma instability, preventing the decline in lung function that occurs in some patients with asthma and preventing side effects from the medications used to treat asthma.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543